1. Home
  2. SKYH vs CRNX Comparison

SKYH vs CRNX Comparison

Compare SKYH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sky Harbour Group Corporation

SKYH

Sky Harbour Group Corporation

HOLD

Current Price

$9.59

Market Cap

324.6M

Sector

Industrials

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.83

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYH
CRNX
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.6M
3.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SKYH
CRNX
Price
$9.59
$35.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$13.83
$74.78
AVG Volume (30 Days)
103.9K
885.6K
Earning Date
03-19-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$95.29
$730.30
Revenue Next Year
$69.22
$179.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.22
$24.10
52 Week High
$14.20
$57.99

Technical Indicators

Market Signals
Indicator
SKYH
CRNX
Relative Strength Index (RSI) 57.23 26.91
Support Level $8.33 $35.43
Resistance Level $9.53 $37.23
Average True Range (ATR) 0.32 1.60
MACD 0.06 -0.02
Stochastic Oscillator 73.39 3.18

Price Performance

Historical Comparison
SKYH
CRNX

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: